Economic aspects of bladder cancer: what are the benefits and costs?
Economic aspects of bladder cancer: what are the benefits and costs?
复制标题
DOI：
10.1007/s00345-009-0395-z
复制
发表时间：
2009-06
影响因子：
3.4
通讯作者：
Stenzl, A.
中科院分区：
文献类型：
--
作者：
Sievert, K. D.;Amend, B.;Nagele, U.;Schilling, D.;Bedke, J.;Horstmann, M.;Hennenlotter, J.;Kruck, S.;Stenzl, A.
关键词：
膀胱癌（BC）是所有癌症中每位患者终身治疗费用最高的癌症。高复发率和持续的侵入性监测要求是这种疾病的经济和人类代价的关键因素。本文的目的是利用最近的文献，以确定机会，提高收益和成本的BC护理。对最近关于（BC）成本效益的出版物进行了PubMed检索。我们回顾了研究，综述，意见书和成本效益分析，主要集中在非肌层浸润性膀胱癌（Ta/T1; NMIBC）。新的诊断工具，如尿液标记物，可能有助于在早期阶段更经济有效地检测BC，然而，这些标记物不能取代膀胱镜检查，这是目前的护理标准。使用氨基乙酰丙酸己酯（Hexaminolevulinate ®）的光动力学诊断工具（PDD）增强了肿瘤的可见性，并改善了经尿道膀胱癌切除术（TURB）的结果，从而可能降低复发率并降低治疗成本。虽然BC研究的重要性已经得到承认，但在过去5年中，研究投资不断减少。BC的经济负担在文献中有很好的特征。这项研究表明，新技术（即，尿基试验、PDD）和治疗方案（膀胱内化疗、辅助免疫疗法）具有显著的潜力来改善BC患者的诊断、治疗和持续监测，具有潜在的临床结果改善和同时的成本节约。需要对BC研究重新产生兴趣和投资，以确保未来的进步。
Bladder cancer (BC) has the highest lifetime treatment costs per patient of all cancers. The high recurrence rate and ongoing invasive monitoring requirement are the key contributors to the economic and human toll of this disease. The purpose of this paper was to utilize the recent literature to identify opportunities for improving the benefits and costs of BC care. A PubMed search was performed of recent publications concerning (BC) cost-effectiveness. We reviewed studies, reviews, opinion papers and cost-effectiveness analyses, focusing primarily on non-muscle-invasive bladder cancer (Ta/T1; NMIBC). New diagnostic tools such as urine markers may assist in more cost-effectively detecting BC at an earlier stage, however, these markers cannot replace the cystoscopy, which is the current standard of care. A photodynamic diagnostic tool (PDD) using hexylaminolevulinate (Hexvix®) enhances tumor visibility and improves transurethral resection of bladder cancer (TURB) results, potentially reducing recurrence rates and lowering treatment costs. While the importance of BC research has been acknowledged, research investment has been continuously reduced during the last 5 years. The economic burden of BC is well-characterized in the literature. This study suggests that new technologies (i.e., urine-based tests, PDD) and therapeutic regimes (intravesical chemotherapy, adjuvant immunotherapy) have significant potential to improve the diagnosis, treatment and on-going monitoring of BC patients, with potential improvements in clinical outcomes and concurrent cost-savings. A renewed interest and investment in BC research are required to ensure future advancements.
登录
查看更多内容
影响因子：
--
作者：
Grasso, Marco
通讯作者：
Grasso, Marco
影响因子：
6.6
作者：
Losa, A;Hurle, R;Lembo, A
通讯作者：
Lembo, A
影响因子：
2.1
作者：
Avritscher, Elenir B. C.;Cooksley, Catherine D.;Elting, Linda S.
通讯作者：
Elting, Linda S.
影响因子：
4.5
作者：
Langa, KM;Fendrick, AM;Hayman, JA
通讯作者：
Hayman, JA
影响因子：
6.6
作者：
Herr, HW
通讯作者：
Herr, HW